What is Zacks Research’s Estimate for TBPH Q4 Earnings?

Theravance Biopharma, Inc. (NASDAQ:TBPH) – Investment analysts at Zacks Research boosted their Q4 2025 earnings per share estimates for Theravance Biopharma in a research report issued to clients and investors on Monday, October 21st. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earnings per share of $0.51 for the quarter, up from their prior forecast of $0.46. The consensus estimate for Theravance Biopharma’s current full-year earnings is ($1.04) per share.

Theravance Biopharma (NASDAQ:TBPH) last posted its earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.25). The business had revenue of $14.26 million for the quarter, compared to analysts’ expectations of $15.81 million. Theravance Biopharma had a negative return on equity of 21.29% and a negative net margin of 73.61%. During the same quarter in the previous year, the firm earned ($0.28) EPS.

A number of other equities research analysts have also recently weighed in on TBPH. Leerink Partners cut shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $15.00 to $10.00 in a research report on Tuesday, August 6th. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Theravance Biopharma in a research report on Monday, September 16th. Leerink Partnrs lowered Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 6th. StockNews.com downgraded Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, August 10th. Finally, TD Cowen cut their target price on shares of Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating on the stock in a report on Tuesday, August 6th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $13.75.

Theravance Biopharma Trading Up 1.6 %

Shares of NASDAQ:TBPH opened at $8.80 on Tuesday. The firm has a 50 day simple moving average of $8.20 and a 200-day simple moving average of $8.76. Theravance Biopharma has a twelve month low of $7.44 and a twelve month high of $11.71. The company has a market capitalization of $430.50 million, a PE ratio of -9.57 and a beta of 0.25.

Insider Transactions at Theravance Biopharma

In other news, major shareholder Eli Samaha bought 999,800 shares of Theravance Biopharma stock in a transaction dated Wednesday, August 7th. The stock was bought at an average price of $7.80 per share, for a total transaction of $7,798,440.00. Following the purchase, the insider now owns 9,511,150 shares of the company’s stock, valued at approximately $74,186,970. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 6.90% of the company’s stock.

Institutional Trading of Theravance Biopharma

Several hedge funds have recently modified their holdings of the business. Kennedy Capital Management LLC lifted its stake in shares of Theravance Biopharma by 3.7% in the first quarter. Kennedy Capital Management LLC now owns 38,202 shares of the biopharmaceutical company’s stock valued at $343,000 after purchasing an additional 1,359 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in shares of Theravance Biopharma by 7.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 49,475 shares of the biopharmaceutical company’s stock worth $444,000 after acquiring an additional 3,532 shares in the last quarter. State Board of Administration of Florida Retirement System grew its holdings in shares of Theravance Biopharma by 28.2% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 22,671 shares of the biopharmaceutical company’s stock worth $203,000 after acquiring an additional 4,990 shares during the period. American Century Companies Inc. increased its stake in Theravance Biopharma by 11.7% in the 2nd quarter. American Century Companies Inc. now owns 57,611 shares of the biopharmaceutical company’s stock valued at $489,000 after purchasing an additional 6,026 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in Theravance Biopharma by 16.6% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 52,876 shares of the biopharmaceutical company’s stock worth $474,000 after purchasing an additional 7,509 shares during the last quarter. 99.10% of the stock is owned by institutional investors and hedge funds.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.